GlobeNewsWire
24 Feb 2026, 17:02 UTC · 30w ago
Verdict
Headline takes no side. We score AB +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
AB Science has identified a plasma biomarker that identifies patients with pro-inflammatory microglia targeted by masitinib in ALS patients.
More positive than 92% of claims this week
The biomarker will be integrated into Phase 3 programs for ALS, progressive multiple sclerosis, and Alzheimer's disease.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 77% of claims this week
The company intends to use the biomarker to potentially establish a surrogate endpoint for efficacy to facilitate regulatory registration.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The company identified a plasma biomarker that could increase the chance of registration and clinical success for masitinib in treating ALS, MS, and Alzheimer's.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3h ago
−5.8%
Price is moving against the score
$36.19 vs $38.41 close before publication (Feb 23) · not market-adjusted
AB chart →